Overview

• Approval was supported by phase 3 Clarity 1 and 2 trials and a six-month Clarity 3 study demonstrating rapid near-vision gains within 30 minutes and lasting benefits without serious treatment-related adverse events.
• Vizz contains 1.44% aceclidina, a predominantly pupil-selective miotic that creates a pinhole effect by constricting the iris sphincter while minimizing ciliary muscle stimulation.
• The product label prescribes one drop per eye followed by a second drop after two minutes once daily, and advises removing contact lenses before application and waiting 10 minutes to reinsert them.
• The most common side effects are instillation-site irritation (20%), dim or blurred vision (16%) and headache (13%), all generally mild and transient.
• Ophthalmologists highlight the drops’ reversibility and suitability for early presbyopia, and call for post-marketing surveillance to monitor long-term safety and real-world effectiveness.